Browse Category

Investment Analysis News 6 December 2025

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Published: December 6, 2025 – For information only, not investment advice. Johnson & Johnson stock (NYSE: JNJ) is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings beats, major acquisitions in neuroscience and oncology, and fresh clinical data in bladder cancer. At the same time, the company is absorbing huge jury verdicts in talc litigation and preparing to spin off its orthopaedics business, setting up a very different J&J for the second half of the decade. Reuters+4Johnson & Johnson Investor Relations+4Johnson & Johnson Investor Relations+4 Below is
Plug Power Stock News Today (December 6, 2025): NASA Deal, AI Data Centers and a New CEO Reframe the PLUG Outlook

Plug Power Stock News Today (December 6, 2025): NASA Deal, AI Data Centers and a New CEO Reframe the PLUG Outlook

Plug Power Inc. (NASDAQ: PLUG) heads into December 2025 trading around $2.20 per share, after another volatile week that saw the hydrogen fuel‑cell specialist lag a rising market but continue a multi‑month rebound from its 2025 lows.MarketWatch The stock is still about 52% below its 52‑week high of $4.58, underscoring just how bruising the last year has been for shareholders.MarketWatch+1 Yet beneath the noise, the story around Plug Power stock has clearly shifted. In just the last few weeks the company has: At the same time, Plug’s latest Q3 2025 results showed some progress on cash burn and adjusted losses,
Circle Internet Group (CRCL) Stock Outlook for December 6, 2025: Volatile Rebound, Analyst Targets & USDC Growth

Circle Internet Group (CRCL) Stock Outlook for December 6, 2025: Volatile Rebound, Analyst Targets & USDC Growth

Circle Internet Group, Inc. (NYSE: CRCL), the fintech behind the USDC and EURC stablecoins, is back on traders’ radar after a sharp rebound this week that followed a bruising November sell‑off. The stock closed around $85.62 on Friday, December 5, down about 2.1% on the day but still up roughly 7% over the past week, according to price data from Investing.com and Quiver Quantitative. Investing.com+1 At current levels, Circle sports a market capitalization of roughly $20–21 billion, with a 52‑week range of $64.00 to $298.99 and a performance profile that underlines just how volatile the name has been since its
Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Updated: December 6, 2025 Tempus AI Inc. (NASDAQ: TEM) has quickly become one of the most closely watched artificial intelligence stocks in healthcare. After a year marked by multiple FDA clearances, strong revenue growth and high-profile partnerships, Wall Street is now debating whether the current share price in the mid‑$70s still leaves meaningful upside. Business Wire+1 Fresh research notes and news items published on December 5–6, 2025—including new institutional buying, updated growth forecasts and a cluster of analyst price targets—are reshaping the conversation around the stock’s outlook heading into 2026. MarketBeat+2Nasdaq+2 Tempus AI at a glance Tempus AI is a
CAVA Group Inc (CAVA) Stock Outlook 2026: Institutional Buying, Q3 Reset and Analyst Price Target Forecasts

CAVA Group Inc (CAVA) Stock Outlook 2026: Institutional Buying, Q3 Reset and Analyst Price Target Forecasts

CAVA Group Inc’s stock has become one of the most volatile stories in U.S. restaurants, swinging from euphoric post‑IPO highs to deep 2025 drawdowns. As of December 6, 2025, the fast‑casual Mediterranean chain sits at the crossroads of rapid unit growth, slowing same‑store sales and a still‑demanding valuation that divides analysts and investors. Below is a detailed look at the latest CAVA stock news, forecasts and analyses as of December 6, 2025. CAVA stock today: price, valuation and volatility CAVA shares finished trading on Friday, December 5, a little above $53 per share, giving the company a market value of
Quantum Computing Inc (QUBT) Stock on December 6, 2025: Earnings Beat, $1.5B Cash, $40 Targets – and Mounting Bubble Fears

Quantum Computing Inc (QUBT) Stock on December 6, 2025: Earnings Beat, $1.5B Cash, $40 Targets – and Mounting Bubble Fears

As of December 6, 2025, Quantum Computing Inc (NASDAQ: QUBT) sits at the center of one of Wall Street’s most speculative stories. The stock closed at about $12.84 on December 5, down roughly 5% on the day, yet still up well into triple digits over the past year, with a 52‑week range of $4.37–$27.15 and a market capitalization around $2.9 billion.StockAnalysis Over the last few weeks, QUBT has delivered a Q3 2025 earnings beat, raised more than $1.25 billion via oversubscribed private placements, announced a landmark commercial quantum‑cybersecurity deal with a top‑five U.S. bank, and attracted new institutional buyers. At
Duke Energy (DUK) Stock on December 6, 2025: Price, Nuclear Push, Rate Hike Fight and 2026 Wall Street Forecasts

Duke Energy (DUK) Stock on December 6, 2025: Price, Nuclear Push, Rate Hike Fight and 2026 Wall Street Forecasts

On December 6, 2025, Duke Energy Corp. (NYSE: DUK) sits at the center of several powerful storylines: a five‑day share price slide, a major North Carolina rate case facing political and industrial pushback, an aggressive new nuclear and storage strategy, and broadly constructive—but not euphoric—analyst forecasts for 2026 and beyond. Below is a detailed look at the latest Duke Energy stock news, forecasts, and analysis as of December 6, 2025. 1. Where Duke Energy Stock Stands Today Duke Energy shares last closed at about $116.52 on Friday, December 5, 2025, down 1.23% on the day and marking a fifth consecutive
Lumen Technologies (LUMN) Stock on December 6, 2025: Price Action, Fresh News, Forecasts and Turnaround Risks

Lumen Technologies (LUMN) Stock on December 6, 2025: Price Action, Fresh News, Forecasts and Turnaround Risks

New York – December 6, 2025 Lumen Technologies Inc. (NYSE: LUMN) remains one of Wall Street’s most hotly debated turnaround stories. After a spectacular multi-year collapse, a massive debt restructuring and a sharp rebound driven by AI and cloud ambitions, the stock is once again swinging sharply as investors digest new products, leadership changes and mixed analyst forecasts. Lumen stock price today: sharp pullback after a big run As of early trading on Saturday, December 6, Lumen shares trade around $8.26, down roughly 6% from the previous close. Based on the latest tape, the stock has an intraday high of
Constellation Energy (CEG) Stock on December 6, 2025: Calpine Deal Cleared, AI Power Demand Surges and Wall Street Sees More Upside

Constellation Energy (CEG) Stock on December 6, 2025: Calpine Deal Cleared, AI Power Demand Surges and Wall Street Sees More Upside

Constellation Energy Corporation (NASDAQ: CEG) has become one of the standout stories in the utility and clean‑energy sector in 2025. As of the close on December 5, 2025, Constellation Energy stock traded at $359.82, giving the company a market capitalization of roughly $110–115 billion and placing it among the world’s largest utilities by value.Companies Market Cap+1 Over the past three years, the stock has delivered a staggering 311% total return, with gains of more than 40% over the last 12 months and close to 50–60% year to date, according to recent valuation work from Simply Wall St.Simply Wall St That
Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences stock (NASDAQ: GILD) is trading near the upper end of its 52‑week range as of early December 2025, supported by stronger guidance, big HIV and liver franchises, and a mixed but important year for its oncology pipeline. At the same time, new deals in cell therapy and targeted protein degradation show management leaning into long‑term cancer bets, even at the cost of a bit of near‑term EPS. Here’s a detailed look at the latest price action, earnings, drug news, analyst forecasts and key risks that matter for GILD into 2026. Gilead Sciences stock price and recent trading As
Enbridge Inc (ENB) Stock on December 6, 2025: Dividend Hike, 2026 Guidance, Line 5 Risks and Analyst Forecasts

Enbridge Inc (ENB) Stock on December 6, 2025: Dividend Hike, 2026 Guidance, Line 5 Risks and Analyst Forecasts

Enbridge Inc. (TSX: ENB; NYSE: ENB) has packed a lot into the first week of December 2025: a new 2026 financial outlook, another dividend increase extending its three-decade growth streak, and fresh scrutiny of its controversial Line 5 pipeline project in Michigan. At the same time, institutional investors are still adding to positions, and analysts see meaningful upside from today’s price — albeit with some caveats around debt and regulation. As of the close on December 5, 2025, Enbridge traded around US$48.09 on the NYSE and C$66.58 on the TSX, keeping it in the upper half of its 52‑week trading
Cisco Systems (CSCO) Stock Near Record Highs on AI Boom: Latest News, Analyst Forecasts and 2026 Outlook as of December 6, 2025

Cisco Systems (CSCO) Stock Near Record Highs on AI Boom: Latest News, Analyst Forecasts and 2026 Outlook as of December 6, 2025

Cisco Systems stock snapshot (December 6, 2025) Cisco Systems, Inc. (NASDAQ: CSCO) is trading at $77.97 as of the latest session, putting the stock just below its all‑time closing high of $78.39 set on November 19, 2025. Macrotrends According to Macrotrends data, the 52‑week high sits at $80.06, only a few percent above today’s price, underscoring how close CSCO is to its historical peak. Macrotrends On a year‑to‑date basis, Cisco shares are up about 31.7% in 2025 (through the close on December 5), a strong rebound after several more muted years. Slick Charts Cisco continues to deliver a mix of
1 205 206 207 208 209 282

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Go toTop